Ascelia Pharma AB (SE:ACE)
:ACE
Want to see SE:ACE full AI Analyst Report?
ACE Stock Chart & Stats
kr3.17
-kr0.11(-3.47%)
At close: 4:00 PM EST
kr3.17
-kr0.11(-3.47%)
Day’s Range― - ―
52-Week Rangekr2.53 - kr5.23
Previous CloseN/A
Volume171.87K
Average Volume (3M)1.75M
Market Cap
kr375.23M
Enterprise Valuekr358.83M
Total Cash (Recent Filing)kr33.89M
Total Debt (Recent Filing)kr689.00K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding133,535,460
10 Day Avg. Volume1,883,755
30 Day Avg. Volume1,753,338
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.26
Revenue Forecast (FY)kr87.22M
Bulls Say, Bears Say
Bulls Say
Lead Product Targets Unmet MRI-contrast NeedOrviglance targets a clear clinical niche—patients who cannot receive gadolinium—giving the company a differentiated development focus. A successful approval/commercialization would create a durable pathway to recurring diagnostic revenues and strategic partnerships in imaging.
Very Low Financial LeverageNear-zero debt provides structural financial flexibility: lower insolvency risk, capacity to fund R&D via equity or partnerships, and reduced fixed financing costs. This advantage endures through development cycles and eases strategic options compared with highly leveraged peers.
Improving Cash Burn Versus Prior YearsA materially reduced burn rate indicates operational tightening or progress that lowers cash needs. Sustained improvement lengthens runway and reduces near-term financing frequency, improving prospects for reaching regulatory or value-inflection milestones.
Bears Say
No Revenue And Large Recurring LossesAs a development-stage company with no commercial sales, losses are structural until product approval/commercial launch. Ongoing negative earnings consume equity and require continual financing, making long-term sustainability contingent on clinical success or external funding.
Weak Cash Generation; Consistent Negative OCF/FCFPersistent negative operating and free cash flow forces reliance on equity raises or partnerships to fund operations. This structural cash shortfall increases dilution risk, constrains long-term planning, and limits ability to scale development or commercial activities without external capital.
Eroding Equity And Deeply Negative ROEDeclining equity and assets reflect capital consumption from losses, weakening the balance sheet over time. Deeply negative ROE signals persistent value destruction that reduces financial resilience, bargaining power for deals, and ability to absorb setbacks without dilutive financing.
Ascelia Pharma AB News
ACE FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
Ascelia Pharma AB lowest stock price was kr2.53 and its highest was kr5.23 in the past 12 months.
What is Ascelia Pharma AB’s market cap?
Ascelia Pharma AB’s market cap is kr375.23M.
When is Ascelia Pharma AB’s upcoming earnings report date?
Ascelia Pharma AB’s upcoming earnings report date is Aug 20, 2026 which is in 67 days.
How were Ascelia Pharma AB’s earnings last quarter?
Ascelia Pharma AB released its earnings results on May 12, 2026. The company reported -kr0.129 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.129.
Is Ascelia Pharma AB overvalued?
According to Wall Street analysts Ascelia Pharma AB’s price is currently Overvalued.
Does Ascelia Pharma AB pay dividends?
Ascelia Pharma AB does not currently pay dividends.
What is Ascelia Pharma AB’s EPS estimate?
Ascelia Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ascelia Pharma AB have?
Ascelia Pharma AB has 133,535,460 shares outstanding.
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Ascelia Pharma AB reported an EPS of -kr0.129 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.372%.
Which hedge fund is a major shareholder of Ascelia Pharma AB?
Currently, no hedge funds are holding shares in SE:ACE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Technical Analysis
Xbrane Biopharma AB
―
Isofol Medical AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―